Avalo Therapeutics, Inc. (AVTX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics targeting the IL-1β pathway. The company's lead asset, abdakibart, is advancing into a Phase 3 registrational program for hidradenitis suppurativa (HS). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Net Loss | $(36,358) | $(55,988) | $(33,914) |
| Net Loss Per Share (Basic/Diluted) | $(0.83) | $(1.75) | $(3.18) |
| Operating Expenses | $31,517 | $52,419 | $33,984 |
| Research & Development (R&D) | $23,418 | $37,466 | $23,195 |
| General & Administrative (G&A) | $8,099 | $14,953 | $10,789 |
| Cash & Cash Equivalents | $85,382 | $85,382 | $42,290 |
| Total Investments (Short & Long Term) | $386,772 | $386,772 | $82,478 |
| Total Liquidity (Cash + Investments) | $472,154 | $472,154 | $124,768 |
| Net Cash Used in Operating Activities | N/A | $(37,679) | $(20,847) |
Material Changes vs. Prior Period
- Equity Financing: In May 2026, the company completed an underwritten public offering of common stock and pre-funded warrants, raising net proceeds of approximately $405 million. This significantly increased total liquidity from $124.8 million in June 2025 to $472.2 million in June 2026.
- R&D Expense Increase: R&D expenses increased by $14.3 million YTD compared to the prior year. This was primarily driven by the recognition of a $10.0 million development milestone payable to Eli Lilly upon the dosing of the first patient in a Phase 3 trial for abdakibart, which was deemed probable as of June 30, 2026.
- Contingent Consideration: The company recognized a $6.6 million charge related to the change in fair value of contingent consideration following the settlement of the AlmataBio Milestone Buyout Option. This was settled via a mix of cash and common stock.
- Derivative Liability: The fair value of the derivative liability (related to out-licensed assets AVTX-007) increased to $18.5 million, resulting in a $0.5 million expense YTD.
- Stock-Based Compensation: Increased to $8.9 million YTD 2026 from $6.0 million YTD 2025, driven by new equity awards and accelerated vesting for former directors.
Guidance, Outlook, and Risks
- Clinical Progress: In Q2 2026, Avalo reported positive topline Phase 2 LOTUS results for abdakibart in HS. The trial met its primary endpoint with statistically significant improvements in HiSCR75 response rates (42.5% combined vs. 25.6% placebo). The company is preparing to initiate pivotal Phase 3 trials.
- Liquidity Outlook: Management expects existing cash, cash equivalents, and investments ($472.2 million) to be sufficient to fund operations into 2029.
- Future Expenses: R&D and G&A expenses are expected to increase as the company advances abdakibart into Phase 3 and expands infrastructure.
- Risks: Key risks include the failure of clinical trials, regulatory delays, the need for additional capital (which may cause dilution), and the uncertainty of fair value measurements for derivative liabilities and contingent consideration.
Investor Verification Checklist
- Verify the probability assessment of the $10.0 million Phase 3 milestone payment to Eli Lilly and its impact on future R&D accruals.
- Review the terms of the AlmataBio Milestone Buyout Agreement and the valuation methodology used for the $6.6 million contingent consideration charge.
- Monitor the burn rate relative to the $472.2 million liquidity position to confirm the runway into 2029.
- Assess the assumptions (probability of success, peak sales forecasts) driving the $18.5 million derivative liability valuation for AVTX-007.
- Confirm the timeline and design of the upcoming Phase 3 registrational program for abdakibart in HS.